

# Michael F Walsh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3174/publications.pdf>

Version: 2024-02-01

69  
papers

7,885  
citations

109321

35  
h-index

98798

67  
g-index

70  
all docs

70  
docs citations

70  
times ranked

13717  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and Functional Significance of TP53 Exon 4 Intron 4 Splice Junction Variants. <i>Molecular Cancer Research</i> , 2022, 20, 207-216.	3.4	4
2	Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 362-371.	2.5	7
3	Inherited TP53 Variants and Risk of Prostate Cancer. <i>European Urology</i> , 2022, 81, 243-250.	1.9	40
4	Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome. <i>Genetics in Medicine</i> , 2022, 24, 1187-1195.	2.4	7
5	Cancer-Causative Mutations Occurring in Early Embryogenesis. <i>Cancer Discovery</i> , 2022, 12, 949-957.	9.4	21
6	Toward more streamlined testing in pediatric oncology. <i>Science Advances</i> , 2022, 8, eabq2807.	10.3	0
7	Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1450-1459.	2.5	10
8	Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers. <i>Nature Communications</i> , 2022, 13, 2485.	12.8	31
9	Concurrent Germline <i>BRCA1</i> and <i>BRCA2</i> and Mismatch Repair Mutations in Young-Onset Pancreatic and Colorectal Cancer: The Importance of Comprehensive Germline and Somatic Characterization to Inform Therapeutic Options. <i>JCO Precision Oncology</i> , 2022, , .	3.0	2
10	Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4267-4277.	7.0	4
11	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. <i>Nature Cancer</i> , 2021, 2, 357-365.	13.2	74
12	Prevalence and Characterization of Biallelic and Monoallelic <i>NTHL1</i> and <i>MSH3</i> Variant Carriers From a Pan-Cancer Patient Population. <i>JCO Precision Oncology</i> , 2021, 5, 455-465.	3.0	10
13	Genetic syndromes predisposing to pediatric brain tumors. <i>Neuro-Oncology Practice</i> , 2021, 8, 375-390.	1.6	3
14	The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. <i>Nature Communications</i> , 2021, 12, 985.	12.8	31
15	Pediatric MDS and bone marrow failure-associated germline mutations in <i>SAMD9</i> and <i>SAMD9L</i> impair multiple pathways in primary hematopoietic cells. <i>Leukemia</i> , 2021, 35, 3232-3244.	7.2	32
16	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. <i>Journal of the National Cancer Institute</i> , 2021, , .	6.3	6
17	Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 945-977.	4.9	12
18	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	1.6	83

#	ARTICLE	IF	CITATIONS
19	Molecular Changes in Retinoblastoma beyond RB1: Findings from Next-Generation Sequencing. <i>Cancers</i> , 2021, 13, 149.	3.7	27
20	Somatic data usage for classification of germ line variants. , 2021, , 169-192.		0
21	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. <i>European Urology Oncology</i> , 2021, 4, 993-1000.	5.4	16
22	The context-specific role of germline pathogenicity in tumorigenesis. <i>Nature Genetics</i> , 2021, 53, 1577-1585.	21.4	44
23	Fumarate hydratase c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. <i>Human Mutation</i> , 2020, 41, 103-109.	2.5	25
24	Reticular dysgenesis caused by an intronic pathogenic variant in AK2. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005017.	1.2	4
25	Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. <i>Journal of Clinical Oncology</i> , 2020, 38, 1398-1408.	1.6	60
26	11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood. <i>Cancer</i> , 2020, 126, 3114-3121.	4.1	23
27	Histone H3K36I mutation in a metastatic histiocytic tumor of the skull and response to sarcoma chemotherapy. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004606.	1.2	8
28	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 286-295.	1.6	397
29	Toward automation of germline variant curation in clinical cancer genetics. <i>Genetics in Medicine</i> , 2019, 21, 2116-2125.	2.4	27
30	Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1934-1943.	7.2	69
31	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	3.0	7
32	ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. <i>Blood Advances</i> , 2019, 3, 2962-2979.	5.2	110
33	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. <i>Nature Medicine</i> , 2019, 25, 1839-1842.	30.7	122
34	Understanding the evolving phenotype of vascular complications in telomere biology disorders. <i>Angiogenesis</i> , 2019, 22, 95-102.	7.2	45
35	A synonymous germline variant PALB2 c.18G>T (p.Gly6=) disrupts normal splicing in a family with pancreatic and breast cancers. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 79-86.	2.5	4
36	Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome. <i>Familial Cancer</i> , 2018, 17, 71-77.	1.9	10

#	ARTICLE	IF	CITATIONS
37	Characterization of a novel germline BRCA1 splice variant, c.5332+4delA. Breast Cancer Research and Treatment, 2018, 168, 543-550.	2.5	5
38	Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. Nature Communications, 2018, 9, 3962.	12.8	142
39	Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes. Human Mutation, 2018, 39, 1542-1552.	2.5	40
40	Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. JCI Insight, 2018, 3, .	5.0	71
41	Myelodysplastic Syndrome, Acute Myeloid Leukemia, and Cancer Surveillance in Fanconi Anemia. Hematology/Oncology Clinics of North America, 2018, 32, 657-668.	2.2	42
42	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncology, 2018, 4, 1228.	7.1	132
43	Health supervision for people with Bloom syndrome. American Journal of Medical Genetics, Part A, 2018, 176, 1872-1881.	1.2	39
44	Duty to Warn in the Era of Next Generation Sequencing. American Journal of Bioethics, 2018, 18, 79-80.	0.9	2
45	Germline <i>SDHA</i> mutations in children and adults with cancer. Journal of Physical Education and Sports Management, 2018, 4, a002584.	1.2	33
46	Germline SAMD9 mutation in siblings with monosomy 7 and myelodysplastic syndrome. Leukemia, 2017, 31, 1827-1830.	7.2	58
47	Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. Clinical Cancer Research, 2017, 23, e62-e67.	7.0	139
48	Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk. Clinical Cancer Research, 2017, 23, e83-e90.	7.0	122
49	Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders. Clinical Cancer Research, 2017, 23, e23-e31.	7.0	93
50	Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions. Clinical Cancer Research, 2017, 23, e14-e22.	7.0	80
51	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	7.4	366
52	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. JAMA Oncology, 2017, 3, 1634.	7.1	148
53	The genomic landscape of pediatric myelodysplastic syndromes. Nature Communications, 2017, 8, 1557.	12.8	143
54	Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clinical Cancer Research, 2017, 23, e98-e106.	7.0	166

#	ARTICLE	IF	CITATIONS
55	Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. <i>Clinical Cancer Research</i> , 2017, 23, e123-e132.	7.0	55
56	Germline <i>BRCA2</i> mutations detected in pediatric sequencing studies impact parents'™ evaluation and care. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001925.	1.2	17
57	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	286
58	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 443-453.	27.0	1,205
59	A Recurrent <i>ERCC3</i> Truncating Mutation Confers Moderate Risk for Breast Cancer. <i>Cancer Discovery</i> , 2016, 6, 1267-1275.	9.4	41
60	Characterization of a novel germline <i>PALB2</i> duplication in a hereditary breast and ovarian cancer family. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 447-456.	2.5	16
61	Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1368-1374.	1.5	49
62	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. <i>JAMA Oncology</i> , 2016, 2, 104.	7.1	270
63	Genomic Biomarkers for Breast Cancer Risk. <i>Advances in Experimental Medicine and Biology</i> , 2016, 882, 1-32.	1.6	42
64	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. <i>Journal of Clinical Oncology</i> , 2016, 34, 2206-2211.	1.6	692
65	Germline <i>ETV6</i> Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. <i>PLoS Genetics</i> , 2015, 11, e1005262.	3.5	128
66	Germline Mutations in Predisposition Genes in Pediatric Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 2336-2346.	27.0	949
67	The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. <i>Nature Communications</i> , 2014, 5, 3630.	12.8	342
68	Incidence of Germline Mutations in Cancer-Predisposition Genes in Children with Hematologic Malignancies: a Report from the Pediatric Cancer Genome Project. <i>Blood</i> , 2014, 124, 127-127.	1.4	9
69	The genomic landscape of hypodiploid acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013, 45, 242-252.	21.4	588